Research ArticleBasic Science Investigation
18F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy
Jelena Levi, Samuel Goth, Lyna Huynh, Tina Lam, Tony L. Huynh, Brailee Schulte and Juliet A. Packiasamy
Journal of Nuclear Medicine June 2021, 62 (6) 802-807; DOI: https://doi.org/10.2967/jnumed.120.249078
Jelena Levi
1CellSight Technologies Incorporated, San Francisco, California; and
Samuel Goth
1CellSight Technologies Incorporated, San Francisco, California; and
Lyna Huynh
1CellSight Technologies Incorporated, San Francisco, California; and
Tina Lam
1CellSight Technologies Incorporated, San Francisco, California; and
Tony L. Huynh
2Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Brailee Schulte
2Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
Juliet A. Packiasamy
1CellSight Technologies Incorporated, San Francisco, California; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue 6
June 1, 2021
18F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy
Jelena Levi, Samuel Goth, Lyna Huynh, Tina Lam, Tony L. Huynh, Brailee Schulte, Juliet A. Packiasamy
Journal of Nuclear Medicine Jun 2021, 62 (6) 802-807; DOI: 10.2967/jnumed.120.249078
Jump to section
Related Articles
Cited By...
- Total-body Dynamic Imaging and Kinetic Modeling of 18F-AraG in Healthy Individuals and a Non-Small Cell Lung Cancer Patient Undergoing Anti-PD-1 Immunotherapy
- Imaging of Activated T Cells
- Longitudinal Imaging of T Cells and Inflammatory Demyelination in a Preclinical Model of Multiple Sclerosis Using 18F-FAraG PET and MRI